Metsera, Inc.
MTSR
Kedudukan dalam Saham
#2573
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Harga Saham
$70.50
Disegerakkan terakhir: 2025-11-14
Modal Pasaran
$7.33B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
33.60%
Negara
US
Perdagangan Metsera, Inc. (MTSR)
Kategori
Healthcare
Sejarah hasil dividen untuk Metsera, Inc. (MTSR)
Hasil dividen (TTM) bagi Metsera, Inc. (simbol saham: MTSR) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Metsera, Inc. (MTSR) dari 2023 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Ubah |
|---|---|---|
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
| Syarikat | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
